Castle Biosciences Announces Pricing of $232 Million Public Offering of Common Stock

Rhea-AI Summary

Castle Biosciences (CSTL) has priced its public offering of 4,000,000 shares at $58.00 each, expected to yield gross proceeds of $232 million. Additionally, underwriters have a 30-day option for 600,000 more shares. Closing is anticipated around December 18, 2020, subject to conditions. The offering is made under a previously effective registration statement with the SEC. SVB Leerink and Baird are leading the offering, with other firms assisting.

Positive

• Gross proceeds expected to be $232 million from the public offering.
• Potential additional funds if underwriters exercise their option for 600,000 shares.

Negative

• The offering may lead to dilution of existing shares, impacting shareholder value.

Castle Biosciences, Inc. (Nasdaq: CSTL), announced today the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $58.00 per share. The gross proceeds to Castle from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Castle, are expected to be $232 million. In addition, Castle has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock at the offering price, less underwriting discounts and commissions. The offering is expected to close on or about December 18, 2020, subject to customary closing conditions.

SVB Leerink and Baird are acting as joint bookrunning managers in the offering. Canaccord Genuity is acting as passive bookrunner and BTIG and Lake Street Capital Markets are acting as co-managers for the offering.

The securities described above are being offered by Castle pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Castle and became effective by rule of the Securities and Exchange Commission (the “SEC”) on December 14, 2020. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from: SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132, or by email at syndicate@svbleerink.com; or Robert W. Baird & Co. Incorporated, Attention: Syndicate Department, 777 East Wisconsin Ave., Milwaukee, WI 53202, by telephone at (800) 792-2473, or by email at syndicate@rwbaird.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Castle Biosciences

Castle Biosciences is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements regarding the completion, timing and expected gross proceeds of the offering. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Castle’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with market conditions and the satisfaction of closing conditions related to the public offering, risks and uncertainties associated with Castle’s business and finances in general, risks associated with the COVID-19 global pandemic, and the other risks described in Castle’s quarterly report on Form 10-Q for the quarterly period ended September 30, 2020, the preliminary prospectus supplement relating to the public offering and other filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Castle undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201215006185/en/

FAQ

What is the share price for Castle Biosciences' offering?

The share price is set at $58.00 for Castle Biosciences' public offering.

How many shares is Castle Biosciences offering?

Castle Biosciences is offering 4,000,000 shares, with an option for an additional 600,000 shares.

When is the expected closing date for the Castle Biosciences offering?

The offering is expected to close on or about December 18, 2020.

What will Castle Biosciences do with the proceeds from the offering?

The press release does not specify the intended use of proceeds from the offering.

Who are the joint bookrunning managers for CSTL's offering?

SVB Leerink and Baird are acting as joint bookrunning managers for the offering.